HS-10382(Part 2: Dose expansion)
Phase 1Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-10382(Part 2: Dose expansion) is one of 44 small molecule programs targeting Myeloid Leukemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
100 competitors in Myeloid Leukemia
#DrugCompanyPhaseTrials
1Iclusig
TakedaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Xospata
AstellasPhase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Busulfex
Akero TherapeuticsPhase 3
Scemblix
NovartisPhase 2
Jakafi
IncytePhase 2
Actos
TakedaPhase 2
Cytosar
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details